VB-111

DRUG3 trials

Sponsors

Vascular Biogenics Ltd. operating as VBL Therapeutics

Conditions

Advanced and/or Metastatic Solid Organ CancerDifferential Thyroid CancerGlioblastoma Multiforme

Phase 1

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Vascular Biogenics Ltd. operating as VBL TherapeuticsAdvanced and/or Metastatic Solid Organ Cancer

Start: 2007-11-30End: 2015-06-30Target: 48Updated: 2015-03-27

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

CompletedNCT01260506

Vascular Biogenics Ltd. operating as VBL TherapeuticsGlioblastoma Multiforme

Start: 2010-12-31End: 2018-12-20Target: 75Updated: 2020-04-24

Phase 2

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

CompletedNCT01229865

Vascular Biogenics Ltd. operating as VBL TherapeuticsDifferential Thyroid Cancer

Start: 2010-12-31End: 2016-06-30Updated: 2018-10-23

Related Papers

Viral Therapy for Glioblastoma

Oncology Times2020-02-26

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Neuro-Oncology2019-12-0768 citations

NIMG-47. VOLUMETRIC ANALYSIS OF PHASE 2 AND 3 TRIALS IN RECURRENT GLIOBLASTOMA TREATED WITH VB-111 WITH OR WITHOUT BEVACIZUMAB OR BEVACIZUMAB MONOTHERAPY

Neuro-Oncology2019-11-01

Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy.

Journal of Clinical Oncology2019-05-201 citations

Treatment through progression with ofranogene obadenovec (VB-111), an anti-cancer viral therapy, significantly attenuates tumor growth in recurrent GBM: Individual phase 2 patient data.

Journal of Clinical Oncology2017-05-20

Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.

Journal of Clinical Oncology2016-05-204 citations